- at San Francisco, California and other locations
- study startedestimated completion:
- Principal Investigator
- D. Montgomery Bissell
The objective of this protocol is to conduct a longitudinal multidisciplinary investigation of the human porphyrias including the natural history, morbidity, pregnancy outcomes, and mortality in people with these disorders.
The porphyrias are a group of rare metabolic diseases that may present in childhood or adult life and are due to deficiencies of enzymes in the heme biosynthetic pathway. The most common manifestations are related to accumulation of intermediates in the pathway and usually occur as acute neurological attacks, or cutaneous photosensitivity. Multiple mutations have been identified in each of the porphyrias. The risk of disability or death from these disorders is significant, in part because diagnosis is often delayed due to lack of adoption of diagnostic testing in clinical practice. Moreover, the natural history of these disorders is not well described and it is not known what determines differences in outcomes. New therapies are needed. For existing therapies, high-quality evidence on short and long term efficacy and safety is generally lacking. Therefore, the purpose of this long-term follow-up study of a large group of patients with the various porphyrias is to provide a better understanding of the natural history of these disorders, as affected by available therapies, and to aid in developing new forms of treatment.
The Office of Rare Diseases (ORD) of the National Institutes of Health (NIH) established a Rare Diseases Clinical Research Network (RDCRN) in collaboration with other NIH Institutes and currently has funded 19 rare diseases clinical research consortia and one Data Management and Coordinating Center. The Porphyrias Consortium was created as part of the RDCRN, to study the human porphyrias. The Porphyrias Consortium is a consortium of the academic institutions listed in the participating institutions table. All Centers in the Porphyrias Consortium are participating in the Longitudinal Study of the Porphyrias. Additional centers may be added if funding is available.
The initial objective of this protocol is to assemble a well-documented group of patients with confirmed diagnoses of specific porphyrias for clinical, biochemical, and genetic studies. The long-term objective is to conduct a longitudinal investigation of the natural history, complications, and therapeutic outcomes in people with acute and cutaneous porphyria.
Acute Porphyrias Cutaneous Porphyrias porphyria acute intermittent coproporphyria variegate erythropoietic protoporphyria hepatoerythropoietic cutanea tarda AIP HCP VP ADP ALAD PCT HEP CEP EPP XLP
You can join if…
- Individuals with a documented diagnosis of a porphyria.
- For each type of porphyria, the inclusion criteria are based on
- clinical features;
- biochemical findings, as documented by laboratory reports (or copies) of porphyria-specific testing performed after 1980 (Absolute values are preferred for diagnostic biochemical thresholds. Fold increases in comparison to an upper(or lower) limit of normal (ULN or LLN) are also acceptable, but are complicated by considerable variation between laboratories in normal limits. Equivocal biochemical measurements may require confirmation by a consortium reference laboratory;)
- molecular findings documenting the identification of a mutation in a porphyria-related gene.
- In addition, an individual or a parent or guardian must be willing to give written informed consent or assent, as appropriate.
- Provision is made for enrolling relatives who may not have symptoms but have biochemical or molecular documentation of a porphyria, or in the case of recessive disorders carry a disease-related mutation.
You CAN'T join if...
- Cases with elevations of porphyrins in urine, plasma or erythrocytes due to other diseases (i.e. secondary porphyrinuria or porphyrinemia), such as liver and bone marrow diseases;
- Patients with a prior diagnosis of porphyria that cannot be documented by review of existing medical records or repeat biochemical or DNA testing.
- University of California, San Francisco accepting new patients
San Francisco, California, 94143, United States
- University of Utah accepting new patients
Salt Lake City, Utah, 84132, United States
- University of Washington accepting new patients
Seattle, Washington, 98195, United States
- University of Texas Medical Branch accepting new patients
Galveston, Texas, 77555, United States
- University of Alabama, Birmingham accepting new patients
Birmingham, Alabama, 35294, United States
- Cleveland Clinic terminated
Cleveland, Ohio, 44195, United States
- Carolinas Medical Center and HealthCare System terminated
Charlotte, North Carolina, 28203, United States
- Wake Forest University Health Sciences accepting new patients
Winston-Salem, North Carolina, 27106, United States
- University of Miami accepting new patients
Miami, Florida, 33136, United States
- Icahn School of Medicine at Mount Sinai accepting new patients
New York, New York, 10029, United States
- accepting new patients
- Start Date
- Completion Date
- Icahn School of Medicine at Mount Sinai
- Website for the Rare Diseases Clinical Research Network (RDCRN) Porphyrias Consortium (PC)
- Lead Scientist
- D. Montgomery Bissell
- Study Type
- Last Updated
- August 1, 2017
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
The study team should get back to you in a few business days.
You will also receive an email with next steps. Check your junk/spam folder if needed.
If you do not hear from the study team, please call 888-689-8273 and tell them you’re interested in study number NCT01561157.